Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) – Research analysts at Zacks Investment Research lifted their FY2017 earnings per share (EPS) estimates for Brainstorm Cell Therapeutics in a research report issued on Tuesday. Zacks Investment Research analyst D. Bautz now forecasts that the biotechnology company will earn ($0.37) per share for the year, up from their previous forecast of ($0.38).
A number of other research firms also recently issued reports on BCLI. ValuEngine upgraded Brainstorm Cell Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, July 22nd. Maxim Group set a $8.00 price objective on Brainstorm Cell Therapeutics and gave the stock a “buy” rating in a report on Saturday, July 22nd.
ILLEGAL ACTIVITY WARNING: This piece was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.chaffeybreeze.com/2017/10/20/brainstorm-cell-therapeutics-inc-bcli-to-post-fy2017-earnings-of-0-37-per-share-zacks-investment-research-forecasts.html.
Brainstorm Cell Therapeutics (BCLI) traded up 0.97% during trading on Friday, reaching $4.18. 25,830 shares of the company’s stock were exchanged. The stock’s 50 day moving average price is $4.12 and its 200 day moving average price is $4.20. The firm’s market cap is $78.11 million. Brainstorm Cell Therapeutics has a 52-week low of $2.06 and a 52-week high of $5.18.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its quarterly earnings results on Tuesday, October 17th. The biotechnology company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.03. During the same quarter last year, the business earned ($0.09) earnings per share.
Institutional investors and hedge funds have recently bought and sold shares of the business. KCG Holdings Inc. raised its holdings in Brainstorm Cell Therapeutics by 4.6% in the first quarter. KCG Holdings Inc. now owns 41,537 shares of the biotechnology company’s stock worth $177,000 after purchasing an additional 1,820 shares in the last quarter. Vanguard Group Inc. raised its holdings in Brainstorm Cell Therapeutics by 2.8% in the second quarter. Vanguard Group Inc. now owns 657,101 shares of the biotechnology company’s stock worth $2,733,000 after purchasing an additional 17,657 shares in the last quarter. Finally, Sphera Funds Management LTD. bought a new position in Brainstorm Cell Therapeutics in the second quarter worth $2,759,000. Institutional investors and hedge funds own 12.69% of the company’s stock.
Brainstorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.
Receive News & Ratings for Brainstorm Cell Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.